Boston Scientific (BSX) Earnings Date & Reports

Key Takeaways

• Revenue beat expectations: Boston Scientific posted Q2 2026 revenue of $5.442 billion, topping the consensus estimate of $5.36 billion and growing 7.5% year-over-year on a reported basis.
• Adjusted EPS exceeded forecasts: Adjusted earnings per share (EPS) came in at $0.86, comfortably above analyst expectations of $0.83 and the company's own guidance range of $0.82 to $0.84.
• Full-year guidance was cut: Management lowered its fiscal 2026 adjusted EPS outlook to $3.28–$3.32 from the prior $3.34–$3.41, citing unexpected headwinds in the WATCHMAN and electrophysiology (EP) businesses.
• WATCHMAN and EP emerge as pressure points: Slower physician referrals for the WATCHMAN left atrial appendage closure device and intensifying competitive dynamics in the U.S. electrophysiology market drove the outlook reduction.
• Restructuring plan announced: Days before earnings, the company unveiled a global restructuring initiative targeting approximately $500 million in annual pre-tax savings by 2029.
• Stock whipsawed in premarket: Shares initially fell roughly 6.6% before recovering into positive territory, reflecting mixed investor reaction to strong quarterly execution against a softer forward outlook.

Earnings Context and Why It Matters

Boston Scientific's Q2 2026 earnings report, released before the market opened on July 29, arrived at a pivotal moment for the $68 billion medical device maker. The stock entered the print down more than 50% over the preceding six months, pressured by a combination of broader macroeconomic uncertainty and company-specific concerns about slowing growth in some of its highest-profile product categories. This quarter was therefore about more than just headline numbers—it was a test of whether management could restore confidence in its growth narrative. The results delivered a split decision: a clean beat on quarterly estimates alongside a meaningful reduction in the full-year outlook, with the focus squarely on challenges in WATCHMAN and the U.S. electrophysiology franchise.

Reported Results

Boston Scientific reported second-quarter 2026 net sales of $5.442 billion, an increase of 7.5% on a reported basis and 7.0% on an organic basis compared to the prior-year period. The figure surpassed the FactSet consensus estimate of $5.36 billion and landed at the high end of the company's guidance range of $5.34 billion to $5.44 billion.

GAAP net income attributable to common stockholders reached $907 million, or $0.61 per diluted share, compared to $797 million, or $0.53 per diluted share, in Q2 2025. On an adjusted basis, which excludes amortization, restructuring-related charges, and certain other items, EPS came in at $0.86, up 15% year-over-year and exceeding both the consensus estimate of $0.83 and management's own guidance of $0.82 to $0.84.

By segment, Cardiovascular revenue—representing roughly two-thirds of total sales—grew 8.3% on a reported basis and 7.8% organically to $3.624 billion. Interventional Cardiology and Vascular Therapies were standout performers, rising 12.1% organically to $1.333 billion, driven by double-digit growth in Coronary Therapies and the AGENT drug-coated balloon. Electrophysiology generated $916 million in sales, up 9.1% organically, though U.S. EP growth was a more modest 3%. WATCHMAN, the company's left atrial appendage closure device, contributed $507 million, with organic growth decelerating to 4.2%—well below its historical trajectory. Cardiac Rhythm Management declined 1.6% organically to $585 million.

The MedSurg segment posted revenue of $1.818 billion, up 5.9% reported and 5.4% organically. Neuromodulation led the segment with 12.2% organic growth, Endoscopy grew 7.0% organically, while Urology lagged at just 0.8% organic growth amid competitive pressures and slower recovery in Sacral Neuromodulation.

Profitability metrics improved meaningfully. Adjusted gross margin expanded 80 basis points to 70.3%, and adjusted operating margin rose 70 basis points to 28.4%. Free cash flow for the quarter totaled $1.29 billion.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors navigate the market more efficiently. The platform allows users to filter thousands of stocks and ETFs using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility measures, and AI-driven trading signals. Whether identifying breakout candidates, tracking momentum shifts, or scanning for stocks exhibiting specific fundamental and technical characteristics, the AI Screener helps surface relevant trade ideas and market opportunities far faster than manual screening methods. For investors monitoring medical device stocks like Boston Scientific, the screener offers a practical way to track sector-wide trends and identify emerging names alongside established players.

Market Reaction and Investor Sentiment

Initial market reaction was volatile and reflected the report's mixed nature. Boston Scientific shares slid as much as 6.6% in premarket trading, dropping to around $43.03 and approaching the stock's 52-week low of $42.20, as investors focused on the guidance reduction. However, as analysts and traders digested the stronger-than-expected quarterly performance and commentary around the restructuring plan, the stock reversed course and rose approximately 3% to 4% in later premarket activity.

The dual reaction underscores the tension in investor sentiment. On one hand, the core business continues to perform well—organic revenue growth of 7% and expanding margins demonstrate operational discipline. On the other hand, the guidance cut concentrated in two key growth franchises—WATCHMAN and electrophysiology—raises legitimate questions about near-term momentum. CEO Mike Mahoney acknowledged the disappointment directly: "This update today is not the outcome we planned or what you have come to expect from us. However, market conditions have evolved quickly and have been challenging to forecast effectively."

Forward Outlook and Key Factors to Monitor

Boston Scientific enters the second half of 2026 with a more cautious posture. Management now expects full-year organic revenue growth of 5% to 6%, down from the prior range of 5% to 7%, and full-year adjusted EPS of $3.28 to $3.32, below the $3.36 consensus. For Q3 2026 specifically, the company guided for organic revenue growth of 3% to 5% and adjusted EPS of $0.80 to $0.82—both below Street expectations.

The outlook reduction is concentrated in two areas. First, the WATCHMAN franchise faces a slowing U.S. left atrial appendage closure (LAAC) market. Newly published clinical evidence on stroke risk in patients with atrial fibrillation is changing physician referral patterns, and a sharp increase in concomitant procedures—those performed alongside other surgeries—is creating operational inefficiencies while displacing standalone procedures. Management expects global WATCHMAN growth to be flat to low single digits for the full year.

Second, in electrophysiology, the rapid adoption of pulsed field ablation (PFA) technology—now an estimated 80% to 85% of the U.S. atrial fibrillation market—has compressed Boston Scientific's window to offset competitive share losses. U.S. EP sales are projected to decline sequentially in Q3, with full-year growth of flat to low single digits.

Investors should monitor several factors going forward. The SIMPLAAFY clinical trial, which could simplify post-implant drug regimens for WATCHMAN patients, is expected to read out in the second half of 2026. The company's global restructuring plan, announced just days before the earnings report, targets $500 million in annual pre-tax savings by 2029, with a material portion reinvested into growth initiatives. Management has also telegraphed that 2027 will likely bring limited adjusted EPS growth, with a more meaningful recovery expected in 2028 as new product launches—including renal denervation, intracardiac echocardiography, and next-generation ablation catheters—begin to contribute.

The base business, which represents approximately 75% of revenue and excludes WATCHMAN and EP, is still expected to grow around 6% in the second half of 2026. This suggests the current headwinds are concentrated rather than systemic, though the market will need to see tangible evidence that management can stabilize and ultimately reaccelerate growth in its two challenged franchises before sentiment meaningfully improves.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations